Vicore Pharma
M├╢lndal
About Vicore Pharma
Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $105.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2025)
- Ticker: sto:VICO
- Website: vicorepharma.com
- Phone: +46 (0) 31 788 05 60
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/vicore-pharma-20747 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.